August 1, 2013
The commercialization process can be an arduous one for pharmaceutical and genetic analysis organizations. Amy Sehnert, MD, Director, Clinical Affairs, Verinata Health, an Illumina Company, will discuss the process at the 5th Annual Personalized Medicine Conference in her presentation: Realizing the Future Today: Development and Implementation of Noninvasive Prenatal Testing.
The presentation will describe key steps and milestones leading to successful commercialization of the verifi® prenatal test, a noninvasive prenatal test that detects multiple fetal chromosomal aneuploidies using a single maternal blood sample from 10 weeks gestation. Evidence from clinical studies as well as clinical laboratory experience that has led to practice opinions and statements by professional medical bodies and coverage decisions by insurers will also be discussed.
The 5th Annual Personalized Medicine Conference will be held in Boston, MA on October 21 – 22, 2013 at the Westin Boston Waterfront. It is an official satellite event of the American Society of Human Genetics Annual Meeting. The event brings together leaders in the field of to explore the ways in which Personalized Medicine is reshaping healthcare. For more information please visit: www.personalized-medicine-conference.com